DBV Technologies S.A. (DBV.PA)
EUR 0.61
(1.17%)
EUR 0.61
(1.17%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 13.01 Million USD | 29.87% |
| 2022 | 10.02 Million USD | -46.38% |
| 2021 | 18.69 Million USD | -43.58% |
| 2020 | 33.13 Million EUR | 19.89% |
| 2019 | 27.63 Million EUR | 530.24% |
| 2018 | 4.38 Million EUR | -20.38% |
| 2017 | 5.5 Million EUR | 9.4% |
| 2016 | 5.03 Million EUR | -8.6% |
| 2015 | 5.5 Million EUR | 6.84% |
| 2014 | 5.15 Million EUR | 149.68% |
| 2013 | 2.06 Million EUR | 27.89% |
| 2012 | 1.61 Million EUR | 51.98% |
| 2011 | 1.06 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 7.59 Million EUR | 12.74% |
| 2024 Q1 | 7.23 Million USD | 10.47% |
| 2023 Q2 | 2.56 Million USD | -11.59% |
| 2023 Q1 | 2.9 Million USD | -71.07% |
| 2023 FY | 13.01 Million USD | 29.87% |
| 2023 Q4 | 6.55 Million USD | 191.12% |
| 2023 Q3 | 2.25 Million USD | -12.21% |
| 2022 FY | 10.02 Million USD | -46.38% |
| 2022 Q4 | 10.02 Million USD | 191.56% |
| 2022 Q1 | 5.42 Million USD | -70.96% |
| 2022 Q2 | 5.3 Million USD | -2.36% |
| 2022 Q3 | 3.43 Million USD | -35.13% |
| 2021 Q2 | 13.68 Million USD | -42.02% |
| 2021 Q1 | 23.6 Million USD | -28.76% |
| 2021 Q3 | 13.12 Million USD | -4.11% |
| 2021 Q4 | 18.69 Million USD | 42.47% |
| 2021 FY | 18.69 Million USD | -43.58% |
| 2020 Q4 | 33.13 Million EUR | 0.0% |
| 2020 Q2 | 25.36 Million EUR | 0.0% |
| 2020 FY | 33.13 Million EUR | 19.89% |
| 2019 Q4 | 27.63 Million EUR | -1.39% |
| 2019 Q2 | 29.59 Million EUR | 0.0% |
| 2019 Q3 | 28.02 Million EUR | -5.31% |
| 2019 FY | 27.63 Million EUR | 530.24% |
| 2018 FY | 4.38 Million EUR | -20.38% |
| 2018 Q4 | 4.38 Million EUR | 0.0% |
| 2018 Q2 | 4.16 Million EUR | 0.0% |
| 2017 Q2 | 5.1 Million EUR | 0.0% |
| 2017 Q4 | 5.5 Million EUR | 0.0% |
| 2017 FY | 5.5 Million EUR | 9.4% |
| 2016 Q4 | 5.03 Million EUR | 0.0% |
| 2016 FY | 5.03 Million EUR | -8.6% |
| 2016 Q2 | 5.36 Million EUR | 0.0% |
| 2015 Q4 | 5.5 Million EUR | 0.0% |
| 2015 Q2 | 5.75 Million EUR | 0.0% |
| 2015 FY | 5.5 Million EUR | 6.84% |
| 2014 Q2 | 2.35 Million EUR | 0.0% |
| 2014 Q4 | 5.15 Million EUR | 0.0% |
| 2014 FY | 5.15 Million EUR | 149.68% |
| 2013 FY | 2.06 Million EUR | 27.89% |
| 2013 Q4 | 2.06 Million EUR | 0.0% |
| 2013 Q2 | 2.04 Million EUR | 0.0% |
| 2012 Q4 | 1.61 Million EUR | 0.0% |
| 2012 FY | 1.61 Million EUR | 51.98% |
| 2012 Q2 | 832.97 Thousand EUR | 0.0% |
| 2011 Q4 | 1.06 Million EUR | 0.0% |
| 2011 FY | 1.06 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -284.03% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 76.528% |
| Adocia SA | 13.08 Million EUR | 0.53% |
| Aelis Farma SA | 4.03 Million EUR | -222.402% |
| Biophytis S.A. | 8.27 Million EUR | -57.42% |
| Advicenne S.A. | 17.42 Million EUR | 25.288% |
| genOway Société anonyme | 7.23 Million EUR | -79.979% |
| IntegraGen SA | 1.12 Million EUR | -1057.482% |
| Medesis Pharma S.A. | 1.2 Million EUR | -984.884% |
| Neovacs S.A. | 650 Thousand EUR | -1902.862% |
| NFL Biosciences SA | 62.17 Thousand EUR | -20838.983% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -198.831% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -379.182% |
| Sensorion SA | 2.86 Million EUR | -353.802% |
| Theranexus Société Anonyme | 3.64 Million EUR | -257.357% |
| TME Pharma N.V. | 1.16 Million EUR | -1016.518% |
| Valbiotis SA | 6.87 Million EUR | -89.279% |
| TheraVet SA | 1.15 Million EUR | -1022.422% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -44.683% |
| argenx SE | 18.1 Million EUR | 28.095% |
| BioSenic S.A. | 28.16 Million EUR | 53.771% |
| Celyad Oncology SA | 902 Thousand EUR | -1343.304% |
| Galapagos NV | 9.59 Million EUR | -35.667% |
| Genfit S.A. | 70.17 Million EUR | 81.449% |
| GeNeuro SA | 7.73 Million EUR | -68.247% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -145.912% |
| Innate Pharma S.A. | 39.89 Million EUR | 67.366% |
| Inventiva S.A. | 37.4 Million EUR | 65.197% |
| MaaT Pharma SA | 14.07 Million EUR | 7.505% |
| MedinCell S.A. | 58.96 Million EUR | 77.92% |
| Nanobiotix S.A. | 50.56 Million EUR | 74.254% |
| Onward Medical N.V. | 16.87 Million EUR | 22.848% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 4.885% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 71.576% |
| Oxurion NV | 12.33 Million EUR | -5.551% |
| Pharming Group N.V. | 155.29 Million EUR | 91.617% |
| Poxel S.A. | 46.9 Million EUR | 72.242% |
| GenSight Biologics S.A. | 18.42 Million EUR | 29.354% |
| Transgene SA | 1.25 Million EUR | -935.688% |
| Financière de Tubize SA | 79.2 Million EUR | 83.562% |
| UCB SA | 3.03 Billion EUR | 99.571% |
| Valneva SE | 208.81 Million EUR | 93.766% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -34159.482% |